From the Guidelines
The recommended dose of Remicade (infliximab) for adults is 5 mg/kg administered intravenously at weeks 0,2, and 6, and then every 8 weeks for psoriasis and psoriatic arthritis, as supported by the most recent and highest quality study 1. This dosing regimen is consistent with guidelines for the treatment of various autoimmune conditions, including rheumatoid arthritis, ankylosing spondylitis, and inflammatory bowel diseases like Crohn's disease and ulcerative colitis.
- Key considerations for treatment with infliximab include:
- Initial induction phase: 5 mg/kg at weeks 0,2, and 6
- Maintenance phase: 5 mg/kg every 8 weeks
- Monitoring for infusion reactions and adjusting the dose or frequency as needed based on patient response
- Screening for tuberculosis and other infections prior to starting treatment, as infliximab suppresses the immune system by blocking tumor necrosis factor-alpha (TNF-α) 1. It's also important to note that some patients may require dose adjustments, with potential increases up to 10 mg/kg or more frequent infusions, depending on their response to treatment 1. Additionally, concurrent administration of methotrexate may help reduce the incidence of infusion reactions and improve efficacy by decreasing the formation of antibodies against infliximab 1.
From the FDA Drug Label
The recommended dose of RENFLEXIS is 5 mg/kg given as an intravenous induction regimen at 0,2 and 6 weeks followed by a maintenance regimen of 5 mg/kg every 8 weeks thereafter for the treatment of adults with moderately to severely active Crohn's disease or fistulizing Crohn's disease The recommended dose of RENFLEXIS is 5 mg/kg given as an intravenous induction regimen at 0,2 and 6 weeks followed by a maintenance regimen of 5 mg/kg every 8 weeks thereafter for the treatment of adult patients with moderately to severely active ulcerative colitis. The recommended dose of RENFLEXIS is 3 mg/kg given as an intravenous induction regimen at 0,2 and 6 weeks followed by a maintenance regimen of 3 mg/kg every 8 weeks thereafter for the treatment of moderately to severely active rheumatoid arthritis. The recommended dose of RENFLEXIS is 5 mg/kg given as an intravenous induction regimen at 0,2 and 6 weeks followed by a maintenance regimen of 5 mg/kg every 6 weeks thereafter for the treatment of active ankylosing spondylitis. The recommended dose of RENFLEXIS is 5 mg/kg given as an intravenous induction regimen at 0,2 and 6 weeks followed by a maintenance regimen of 5 mg/kg every 8 weeks thereafter for the treatment of psoriatic arthritis. The recommended dose of RENFLEXIS is 5 mg/kg given as an intravenous induction regimen at 0,2 and 6 weeks followed by a maintenance regimen of 5 mg/kg every 8 weeks thereafter for the treatment of chronic severe (i.e., extensive and/or disabling) plaque psoriasis.
The recommended dose of Remicade (Infliximab) for adults varies by condition:
- Crohn's disease: 5 mg/kg every 8 weeks
- Ulcerative colitis: 5 mg/kg every 8 weeks
- Rheumatoid arthritis: 3 mg/kg every 8 weeks
- Ankylosing spondylitis: 5 mg/kg every 6 weeks
- Psoriatic arthritis: 5 mg/kg every 8 weeks
- Plaque psoriasis: 5 mg/kg every 8 weeks 2 2
From the Research
Remicade Dose for Adults
The recommended dose of Remicade (Infliximab) for adults varies depending on the condition being treated.
- For Crohn's disease, the recommended dose is 5 mg/kg, with an induction regimen of 3 doses at 0,2, and 6 weeks, followed by maintenance dosing every 8 weeks 3.
- For rheumatoid arthritis, the recommended dose is 3-5 mg/kg, administered intravenously, generally in a schedule with initial infusions at 0,2, and 6 weeks, followed by administration once every 8 weeks 4, 5.
- The dose may be adjusted based on the patient's response to treatment, with some patients requiring higher doses of up to 10 mg/kg 3.
Administration and Pharmacokinetics
Remicade is administered intravenously, and its pharmacokinetics have been studied in various patient populations.
- The apparent volume of distribution of infliximab is low, representing the intravascular space, and its elimination half-life is 7-12 days 6.
- The drug is eliminated through degradation by unspecific proteases, and its serum concentrations increase in proportion to the infused dose, indicating linear pharmacokinetics 6.
- Co-medication with methotrexate may delay the decline in serum concentrations of infliximab, and trough concentrations above 1 microg/mL may be used as a therapeutic target 6.